236 related articles for article (PubMed ID: 32319845)
1. A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer.
de Vos-Geelen J; Hoebers FJP; Geurts SME; Hoeben A; de Greef BTA; Voncken FEM; Bogers JHA; Braam PM; Muijs CKT; de Jong MA; Kasperts N; Rozema T; Jeene PM; Blom GJ; van Dieren JM; Hulshof MCCM; van Laarhoven HWM; Grabsch HI; Lemmens VEPP; Tjan-Heijnen VCG; Nieuwenhuijzen GAP
Acta Oncol; 2020 Aug; 59(8):895-903. PubMed ID: 32319845
[No Abstract] [Full Text] [Related]
2. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and Outcomes in Patients With and Without Esophageal Stents in Locally Advanced Esophageal Cancer.
Francis SR; Orton A; Thorpe C; Stoddard G; Lloyd S; Anker CJ
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):884-894. PubMed ID: 28864404
[TBL] [Abstract][Full Text] [Related]
4. Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus.
Münch S; Pigorsch SU; Devečka M; Dapper H; Weichert W; Friess H; Braren R; Combs SE; Habermehl D
Radiat Oncol; 2018 Aug; 13(1):139. PubMed ID: 30068371
[TBL] [Abstract][Full Text] [Related]
5. Tolerability and efficacy of concurrent chemoradiotherapy comparing carboplatin/paclitaxel versus platinum/5-FU regimen for locally advanced esophageal and esophagogastric junction cancers.
Tamtai A; Jiarpinitnun C; Hiranyatheb P; Unwanatham N; Sirachainun E; Supsamutchai C; Pattaranutaporn P; Ngamphaiboon N
Med Oncol; 2017 Sep; 34(9):157. PubMed ID: 28785986
[TBL] [Abstract][Full Text] [Related]
6. Comparison of definitive chemoradiotherapy and radiotherapy alone in patients older than 75 years with locally advanced esophageal carcinoma: A retrospective cohort study.
Zhao Q; Hu G; Xiao W; Chen Y; Shen M; Tang Q; Ning X
Medicine (Baltimore); 2017 Sep; 96(35):e7920. PubMed ID: 28858114
[TBL] [Abstract][Full Text] [Related]
7. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.
Suntharalingam M; Winter K; Ilson D; Dicker AP; Kachnic L; Konski A; Chakravarthy AB; Anker CJ; Thakrar H; Horiba N; Dubey A; Greenberger JS; Raben A; Giguere J; Roof K; Videtic G; Pollock J; Safran H; Crane CH
JAMA Oncol; 2017 Nov; 3(11):1520-1528. PubMed ID: 28687830
[TBL] [Abstract][Full Text] [Related]
8. Patterns of recurrence following definitive chemoradiation for patients with proximal esophageal cancer.
de Vos-Geelen J; Geurts SME; Nieuwenhuijzen GAP; Voncken FEM; Bogers JA; Braam PM; Muijs CT; de Jong MA; Kasperts N; Rozema T; Blom GJ; Bouwense SAW; Valkenburg-van Iersel LBJ; Jeene PM; Hoebers FJP; Tjan-Heijnen VCG
Eur J Surg Oncol; 2021 Aug; 47(8):2016-2022. PubMed ID: 33583629
[TBL] [Abstract][Full Text] [Related]
9. Intensity-modulated radiotherapy combined with paclitaxel and platinum treatment regimens in locally advanced esophageal squamous cell carcinoma.
Chen J; Su T; Lin Y; Wang B; Li J; Pan J; Chen C
Clin Transl Oncol; 2018 Mar; 20(3):411-419. PubMed ID: 28779422
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma.
Blom RL; Sosef MN; Nap M; Lammering G; van den Berkmortel F; Hulshof MC; Meijer SL; Wilmink HW; van Berge Henegouwen MI
Dis Esophagus; 2014; 27(4):380-7. PubMed ID: 24006852
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.
Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K
JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer.
Noronha V; Prabhash K; Joshi A; Patil VM; Talole S; Nakti D; Sahu A; Shah S; Ghosh-Laskar S; Patil PS; Mehta SA; Jambhekar N; Mahajan A; Purandare N
Oncol Res; 2016; 23(4):183-95. PubMed ID: 27053347
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.
Zhu HT; Ai DS; Tang HR; Badakhshi H; Fan JH; Deng JY; Zhang JH; Chen Y; Zhang Z; Xia Y; Guo XM; Jiang GL; Zhao KL
World J Gastroenterol; 2017 Jan; 23(3):540-546. PubMed ID: 28210091
[TBL] [Abstract][Full Text] [Related]
15. Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
Smit JK; Muijs CT; Burgerhof JG; Paardekooper G; Timmer PR; Muller K; Woutersen D; Mul VE; Beukema JC; Hospers GA; van Dijk BA; Langendijk JA; Plukker JT
Ann Surg Oncol; 2013 Jun; 20(6):1985-92. PubMed ID: 23274534
[TBL] [Abstract][Full Text] [Related]
16. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer.
Beckham TH; Barney C; Healy E; Wolfe AR; Branstetter A; Yaney A; Riaz N; McBride SM; Tsai CJ; Kang J; Yu Y; Chen L; Sherman E; Dunn L; Pfister DG; Tan J; Rupert R; Bonomi M; Zhang Z; Lobaugh SM; Grecula JC; Mitchell DL; Wobb JL; Miller ED; Blakaj DM; Diavolitsis VM; Lee N; Bhatt AD
Int J Cancer; 2020 Jul; 147(1):107-115. PubMed ID: 31609479
[TBL] [Abstract][Full Text] [Related]
17. Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012.
Brower JV; Chen S; Bassetti MF; Yu M; Harari PM; Ritter MA; Baschnagel AM
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):985-993. PubMed ID: 27869098
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
Athauda A; Watkins D; Mohammed K; Chau I; Starling N; Rao S; Tait D; Aitken K; Cunningham D
Anticancer Res; 2018 Oct; 38(10):5943-5949. PubMed ID: 30275223
[TBL] [Abstract][Full Text] [Related]
19. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
Voncken FEM; van der Kaaij RT; Sikorska K; van Werkhoven E; van Dieren JM; Grootscholten C; Snaebjornsson P; van Sandick JW; Aleman BMP
Am J Clin Oncol; 2018 Sep; 41(9):919-926. PubMed ID: 28763327
[TBL] [Abstract][Full Text] [Related]
20. Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients.
Modesto A; Dalmasso C; Lusque A; Vieillevigne L; Izar F; Moyal E; Carrère N; Guimbaud R; Rives M
Cancer Radiother; 2020 Apr; 24(2):88-92. PubMed ID: 32156457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]